[Form 4] Amylyx Pharmaceuticals, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Joshua B. Cohen, Co‑Chief Executive Officer and Director of Amylyx Pharmaceuticals, Inc. (AMLX), reported two automatic sales of common stock tied to the vesting of restricted stock units on 09/30/2025. The Form 4 shows a sale of 29,733 shares at a weighted average price of $14.3433 and a sale of 200 shares at a weighted average price of $14.9975; the filings state those sales were automatic to satisfy tax withholding obligations. After the transactions the reporting person beneficially owned 3,325,347 shares according to the Form 4. The filing notes the trades occurred across multiple execution prices within the ranges disclosed and that detailed breakdowns can be provided to the SEC on request.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Cohen Joshua B

(Last) (First) (Middle)

C/O AMYLYX PHARMACEUTICALS, INC.

43 THORNDIKE STREET

(Street)

CAMBRIDGE MA 02141

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Amylyx Pharmaceuticals, Inc. [ AMLX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Co-Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/30/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/30/2025		S(1)		29,733(1)	D	$14.3433(2)	3,325,547	D
Common Stock	09/30/2025		S(1)		200(1)	D	$14.9975(3)	3,325,347	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.99 to $14.95. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.995 to $15.00. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

	/s/ Joshua B. Cohen	10/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did AMLX insider Joshua B. Cohen report on Form 4?

He reported two automatic sales on 09/30/2025: 29,733 shares at a weighted average price of $14.3433 and 200 shares at a weighted average price of $14.9975.

Why were the AMLX shares sold by the reporting person?

The Form 4 states the shares were sold automatically to cover tax withholding obligations related to the vesting of restricted stock units.

How many AMLX shares does Joshua B. Cohen beneficially own after these transactions?

Following the reported transactions the Form 4 shows he beneficially owned 3,325,347 shares.

Did the filing report single execution prices for the sales?

No; the filing reports weighted average prices and discloses execution price ranges ($13.99–$14.95 and $14.995–$15.00) with the note that a full breakdown can be provided to the SEC on request.

When was the Form 4 signed?

The signature block shows the Form 4 was signed by Joshua B. Cohen on 10/02/2025.